Better preservation of erectile function in localized prostate cancer patients with modern proton therapy: Is it cost‐effective?
Authors:
- 1 August 2022
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 82 (15) , 1438-1446
Abstract
Background: Stereotactic body radiation therapy (SBRT) has gradually been recognized as favorable curative treatment for localized prostate cancer (PC). However, the high rate of erectile dysfunction (ED) after traditional photon‐based SBRT remains an ongoing challenge that greatly impacts the quality of life of PC survivors. Modern proton therapy allows higher conformal SBRT delivery and has the potential to reduce ED occurrence but its cost‐effectiveness remains uninvestigated.Methods: A Markov decision model was designed to evaluate the cost‐effectiveness of proton SBRT versus photon SBRT in reducing irradiation‐related ED. Base‐case evaluation was performed on a 66‐year‐old (median age of PC) localized PC patient with normal pretreatment erectile function. Further, stratified analyses were performed for different age groups (50, 55, 60, 65, 70, and 75 years) and threshold analyses were conducted to estimate cost‐effective scenarios. A Chinese societal willingness‐to‐pay (WTP) threshold (37,653 US dollars [$])/quality‐adjusted life‐year [QALY]) was adopted.Results: For the base case, protons provided an additional 0.152 QALY at an additional cost of $7233.4, and the incremental cost‐effectiveness ratio was $47,456.5/QALY. Protons was cost‐effective for patients ≤62‐year‐old at the WTP of China (≤66‐year‐old at a WTP of $50,000/QALY; ≤73‐year‐old at a WTP of $100,000/QALY). For patients at median age, once the current proton cost ($18,000) was reduced to ≤$16,505.7 or the patient had a life expectancy ≥88 years, protons were cost‐effective at the WTP of China.Conclusions: Upon assumption‐based modeling, the results of current study support the use of proton SBRT in younger localized PC patients who are previously potent, for better preservation of erectile function. The findings await further validation using data from future comparative clinical trials.Keywords
Funding Information
- National Natural Science Foundation of China (81672872, 81872384, 81872464, 82073220)
This publication has 35 references indexed in Scilit:
- Erectile function, incontinence, and other quality of life outcomes following proton therapy for prostate cancer in men 60 years old and youngerCancer, 2012
- Treatment decision‐making for localized prostate cancer: What younger men choose and whyThe Prostate, 2011
- Sexual Function After Stereotactic Body Radiotherapy for Prostate Cancer: Results of a Prospective Clinical TrialInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2010
- Age-Related Changes in General and Sexual Health in Middle-Aged and Older Men: Results from the European Male Ageing Study (EMAS)The Journal of Sexual Medicine, 2010
- Clinical Interpretation of the Expanded Prostate Cancer Index Composite-Short Form Sexual Summary ScoreJournal of Urology, 2009
- International survey on willingness‐to‐pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?Health Economics, 2009
- Sex life after 65: How does erectile dysfunction affect ageing and elderly men?The Aging Male, 2009
- Treatment failure after primary and salvage therapy for prostate cancerCancer, 2007
- Erectile dysfunction after radiotherapy for prostate cancer and radiation dose to the penile structures: A critical reviewRadiotherapy and Oncology, 2007
- Sexual function after external-beam radiotherapy for prostate cancer: What do we know?Critical Reviews in Oncology/Hematology, 2006